IDEAYA Biosciences (NASDAQ:IDYA) has disclosed preliminary financial results in a recent SEC filing dated July 9, 2024.

As of June 30, 2024, the company estimates having approximately $952.7 million in cash, cash equivalents, and marketable securities.

The company highlighted that these figures are based on preliminary assessments and have not yet been audited.

Additionally, IDEAYA Biosciences announced it has raised about $37.2 million through its "at-the-market" offering, selling 922,000 shares at an average price of $40.40 per share.

The company also stated that it still has approximately $182.1 million of common stock available for future sales under this offering.